Prothrombin time (PT)/ international normalized ration (INR) < . x ULN and partial thromboplastin time (PTT) (activated [a]PTT) < . x ULN
Patients must have the following tests within  days prior to registration to obtain baseline measurements:\r\n* Prothrombin time (PT)/partial thromboplastin time (PTT)/international normalized ratio (INR)/fibrinogen (all patients)\r\n* Neurologic assessment
Partial thromboplastin time (PTT) / prothrombin time (PT) =< . x ULN or international normalized ratio (INR) < . x ULN for patients who are not receiving therapeutic anticoagulation. Patients receiving therapeutic anticoagulation should be on a stable dose.
Patients must have adequate coagulation (international normalized ratio (INR) or prothrombin time (PT), partial thromboplastin time (PTT) ?. times ULN)
The subject has prothrombin time (PT)/international normalized ratio (INR) or partial thromboplastin time (PTT) test >= . x the laboratory ULN within  days before the first dose of cabozantinib
Prothrombin time (PT) / partial thromboplastin time (PTT); PT such that international normalized ratio (INR) =< . x ULN (unless a patient is on therapeutic warfarin) or a PTT =< . x ULN
The subject has prothrombin time (PT)/international normalized ratio (INR) or partial thromboplastin time (PTT) test >= . x the laboratory ULN within  days before the first dose of study treatment
Prothrombin time (PT)/partial thromboplastin time (PTT) ? .  ULN (unless receiving anticoagulation therapy, if receiving anticoagulation therapy, eligibility will be based upon international normalized ratio [INR]).
The participant has prothrombin time (PT)/international normalized ratio (INR) or partial thromboplastin time (PTT) test >= . x the laboratory ULN within  days before the first dose of study treatment
Adequate coagulation function, defined by prothrombin time (PT)/international normalized ratio (INR), partial thromboplastin time (PTT), or thrombin time (TT) of ?.  ULN
Prothrombin time (PT)/international normalized ratio (INR) < . x ULN and partial thromboplastin time (PTT) (activated [a]PTT) < . x ULN
International normalized ratio (INR) ? . and partial thromboplastin time (PTT) ? . x ULN. Prothrombin time (PT) may be used instead of INR if ? . x ULN.
PHASE I: Prothrombin time (PT) (or international normalized ratio [INR]) and partial thromboplastin time (PTT) =< . x ULN
Subject has prothrombin time/International Normalized Ratio or partial thromboplastin time test results at screening ?. x ULN.
Prothrombin time (PT) or international normalized ratio (INR), partial thromboplastin time (PTT) =< . x ULN
Adequate coagulation function as defined by International Normalized Ratio ?. or prothrombin time ?. x ULN, and partial thromboplastin time ?. x ULN
Coagulation parameters: international normalized ratio (INR) > , prothrombin time (PT) and partial thromboplastin time (PTT) > % of deviation of institutional ULN
Prothrombin time (PT)/ international normalized ratio (INR) or partial thromboplastin time (PTT) test >= . x the laboratory ULN within  days before the first dose of study treatment.
Prothrombin time (PT)/international normalized ratio (INR) or partial thromboplastin time (PTT) test =< . x ULN
Within  days before the first dose of study treatment: Prothrombin time (PT)/international normalized ratio (INR) or partial thromboplastin time (PTT) test < . x the ULN within  days before the first dose of study treatment
Prothrombin time (PT)/international normalized ratio (INR) < . x ULN and partial thromboplastin time (PTT) (activated [a]PTT) < . x ULN (unless abnormalities are unrelated to coagulopathy or bleeding disorder).
Prothrombin time/international normalized ratio (PT/INR) < . x ULN and partial thromboplastin time (PTT) (activated [a]PTT) < . x ULN
FULL STUDY INCLUSION CRITERIA: International normalized ratio (INR) or prothrombin time (PT) =< . x ULN (Common Terminology Criteria for Adverse Events [CTCAE] grade =< )\r\n* Note: patients on stable dose of anti-coagulation therapy will be allowed to participate if they have no sign of bleeding or clotting and INR / PT and partial thromboplastin time (PTT) / activated (a)PTT test results are compatible with the acceptable benefit-risk ratio at the investigators discretion
Prothrombin time (PT)/ international normalized ratio (INR) and partial thromboplastin time (PTT) test =< . ULN
Prothrombin time (PT) or international normalized ratio (INR) or partial thromboplastin time ?. x ULN. Patients on a stable, maintenance regimen of anticoagulant therapy for at least  days prior to study drug administration may have PT/INR measurements >. x ULN if, in the opinion of the Investigator, the patient is suitable for the study. An adequate rationale must be provided to the Sponsor prior to randomization.
Abnormal coagulation parameters (prothrombin time [PT] >  seconds, partial thromboplastin time [PTT] >  seconds, and/or international normalized ratio [INR] > .)
Prothrombin time (PT)/international normalized ration (INR) < . x ULN and partial thromboplastin time (PTT) (activated [a]PTT) < . x ULN
The subject has prothrombin time (PT)/international normalized ratio (INR) or partial thromboplastin time (PTT) test >= . x the laboratory ULN within  days before the first dose of study treatment
Prothrombin time (PT) with an international normalized ratio (INR) =< . and a partial thromboplastin time (PTT) of =< . times the ULN; for patients on full-dose oral anti-coagulation (such as warfarin or rivaroxaban), in-range INR (usually between  and ) and a PTT < . times the ULN
Prothrombin time (PT)/international normalized ratio (INR) and partial thromboplastin time (PTT) =< . X ULN; subjects receiving anticoagulation treatment may be allowed to participate with INR established within the therapeutic range prior to randomization
Prothrombin time (PT)/international normalized ratio (INR) or partial thromboplastin time (PTT) test >= . x the laboratory ULN within  days before the first dose of study treatment
Prothrombin time (PT)/international normalized ratio (INR) and partial thromboplastin time (PTT) =< . x institutional ULN
The subject has prothrombin time (PT)/ International Normalized Ratio (INR) or partial thromboplastin time (PTT) test >= . x the laboratory ULN within  days before the first dose of study treatment
Prothrombin time (PT)/international normalized ratio (INR) and partial thromboplastin time (PTT) =< . x institutional ULN
The subject has prothrombin time (PT)/International Normalized Ratio (INR) or partial thromboplastin time (PTT) test >= . x the laboratory ULN within  days before the first dose of study treatment
Abnormal prothrombin time (PT) (international normalized ratio [Inr]) > . INR or partial thromboplastin time (PTT) >  seconds (sec) (may be corrected with flash frozen plasma [FFP], cryoprecipitate, vitamin K, etc)
Prothrombin time (PT)/international normalized ratio (INR) < . x institutional ULN and partial thromboplastin time (PTT) (activated [a]PTT) < . x institutional ULN
Prothrombin time (PT)/international normalized ratio (INR); partial thromboplastin time (PTT) =< .; =< . x ULN
Prothrombin time (PT)/international normalized ratio (INR) and partial thromboplastin time (PTT) < . x ULN for age
Prothrombin time (PT)/international normalized ratio (INR) and partial thromboplastin time (PTT) ? . x ULN (except for subjects receiving anticoagulation therapy)
International normalized ratio (INR) or prothrombin time (PT) =< . x ULN unless on anticoagulation therapy, in which case PT or partial thromboplastin time (PTT) should be in the therapeutic range
The subject has prothrombin time (PT)/institutional normalized ratio (INR) or partial thromboplastin time (PTT) test >= . x the laboratory ULN within  days before the first dose of study treatment
INR (prothrombin time ratio) or partial thromboplastin time (PTT) > . x ULN (Please note: patients with hematopoietic cell transplantation (Hct) < %, WBC < /mm/^ and platelets < ,/mm^ immediately prior to leukapheresis. The procedure may be deferred.)
Prothrombin time (PT)/international normalized ratio (INR) less than or equal to . x ULN and partial thromboplastin time (PTT) (activated [a]PTT) less than or equal to . x ULN
Prothrombin time (PT)/international normalized ratio (INR) and partial thromboplastin time (PTT) performed within  weeks prior to starting study therapy must be =< . x ULN
The subject has prothrombin time (PT)/international normalized ratio (INR) or partial thromboplastin time (PTT) test >= . x the laboratory ULN =<  days before the first dose of study treatment
International normalized ratio (INR) or partial thromboplastin time (PTT)/prothrombin time (PT) =< . ULN, unless the patient is on stable therapeutic dose of warfarin
International normalized ratio INR/ prothrombin time (PT)/ partial thromboplastin time (PTT) each < . x ULN
Prothrombin time/international normalized ratio (PT/INR) and partial thromboplastin time (PTT) =< . x institutional ULN
Prothrombin time (PT)/international normalized ratio (INR) and partial thromboplastin time (PTT) =< . x institutional ULN; subjects receiving anticoagulation treatment may be allowed to participate with INR established within the therapeutic range prior to randomization
The subject has prothrombin time (PT)/international normalized ratio (INR) or partial thromboplastin time (PTT) test results at screening >= . x the laboratory ULN
Active bleeding disorder as determined by abnormal prothrombin time, partial thromboplastin time, international normalized ratio (INR) or platelet count (as determined by institutional lab parameters) at the time of screening
Prothrombin time (PT)/international normalized ratio (INR) and partial thromboplastin time (PTT) =< . x institutional ULN
Prothrombin time (PT)/international normalized ratio (INR) and partial thromboplastin time (PTT) =< . x institutional ULN; subjects receiving anticoagulation treatment may be allowed to participate with PT/INR/PTT established within the therapeutic range prior to randomization; subjects will be eligible if it is determined by a hematologist that the cause is not associated with clinical bleeding (e.g., deficiency of factor XII), within  weeks of the first dose of study treatment
Prothrombin time (PT)/international normalized ratio (INR) and partial thromboplastin time (PTT) =< . x institutional ULN; subjects receiving anticoagulation treatment may be allowed to participate with INR established within the therapeutic range prior to randomization
Prothrombin time (PT) such that international normalized ratio (INR) is =< . x ULN (or an in-range INR, usually between  and , if a patient is on a stable dose of therapeutic warfarin) and a partial thromboplastin time (PTT) < . x ULN
Other: INR (prothrombin time ratio) or partial thromboplastin time (PTT) >. x ULN
Other: INR (prothrombin time ratio) or partial thromboplastin time (PTT) >. x ULN.
Other: INR (prothrombin time ratio) or partial thromboplastin time (PTT) >. x ULN
Coagulation parameters: international normalized ratio (INR) =< , prothrombin time (PT) and partial thromboplastin time (PTT) < . X institutional ULN
Prothrombin time (PT)/partial thromboplastin time (PTT)/international normalized ratio (INR) =< . x ULN
The subject has prothrombin time (PT)/international normalized ratio (INR) or partial thromboplastin time (PTT) test >= .  the laboratory ULN within  days before the first dose of study treatment
The following laboratory values obtained =<  days prior to randomization\r\n* Prothrombin time (PT)/partial thromboplastin time (PTT)/international normalized ratio (INR) =< . X ULN if not anticoagulated; within local institutional guidelines per local physician if anticoagulated
Prothrombin time (PT)/international normalized ratio (INR) and partial thromboplastin time (PTT) =< . x ULN unless on anticoagulation medication with stable dosing for at least one month; in addition, patient must be able to stop taking medication for up to a week in order to have percutaneous biopsies of tumor tissue performed
No patients will have coagulation parameters: international normalized ratio (INR) > , prothrombin time (PT) and partial thromboplastin time (PTT) > % deviation of the institutional ULN
Prothrombin time (PT)/international normalized ratio (INR) < . x ULN and partial thromboplastin time (PTT) < . x ULN
Prothrombin time (PT)/international normalized ratio (INR) and partial thromboplastin time (PTT) =< . x institutional ULN
International normalized ratio (INR) < , prothrombin time (PT) <  sec, and partial thromboplastin time (PTT) <  sec
The subject has prothrombin time (PT)/international normalized ratio (INR) or partial thromboplastin time (PTT) test >= . x the institutional ULN =<  days before the first dose of study treatment, unless PT/PTT prolongation known to be secondary to conditions not associated with increased bleeding risk (as on antiphospholipid antibody syndrome)
The subject has prothrombin time (PT)/international normalized ratio (INR) or partial thromboplastin time (PTT) test results at screening >= .  the laboratory ULN within  days before the first dose of study treatment
The participant has prothrombin time (PT)/international normalized ratio (INR) or partial thromboplastin time (PTT) test results at screening >= . X the laboratory ULN
Prothrombin time (PT) such that international normalized ratio (INR) is =< . (or an in-range INR, usually between  and , if a patient is on a stable dose of therapeutic warfarin for management of venous thrombosis) and a partial thromboplastin time (PTT) < . x ULN
Prothrombin time (PT)/international normalized ratio (INR)/partial thromboplastin time (PTT) within . X the ULN unless a subject is receiving Coumadin and has stable INR which is in range for the desired level of anticoagulation
Subjects must have adequate coagulation as assessed by: international normalized ratio (INR) or prothrombin time (PT) <=. times ULN (CTCAE Grade <=), partial thromboplastin time (PTT) <=. x ULN (CTCAE Grade <=)
International normalized ratio (INR) > , prothrombin time (PT) and partial thromboplastin time (PTT) > % of deviation of institutional ULN
Normal partial thromboplastin time (PTT) and either international normalized ratio (INR) or prothrombin time (PT) < . x ULN
The participant has prothrombin time (PT)/international normalized ratio (INR) or partial thromboplastin time (PTT) test >= . the laboratory ULN within  days before the first dose of study treatment
The subject has prothrombin time (PT)/international normalized ratio (INR) or partial thromboplastin time (PTT) test results at screening >= . x the laboratory ULN
TPI  may interfere with Coumadin dosing and patients who are taking this combination will require monitoring of their prothrombin time (PT), partial thromboplastin time (PTT), and international normalized ratio (INR)
The subject has prothrombin time (PT)/international normalized ratio (INR) or partial thromboplastin time (PTT) test >= . x the laboratory ULN within  days before the first dose of study treatment
Prothrombin time (PT)-international normalized ratio (INR)/partial thromboplastin time (PTT) < . x ULN except in patients receiving active anticoagulation
Coagulation parameters: International normalised ratio (INR) <  and partial prothrombin Time (PTT) = xULN
Prothrombin time (PT)/International normalized ratio (INR) and partial thromboplastin time (PTT) <=.xULN
Coagulation parameters: International normalized ratio (INR) > , prothrombin time (PT) and partial thromboplastin time (PTT) > % of deviation of institutional ULN
The subject has prothrombin time (PT)/international normalized ratio (INR) or partial thromboplastin time (PTT) test results at screening that are >= . x ULN
Prothrombin time (PT)/international normalized ratio (INR), partial thromboplastin time (PTT) =< . x ULN
Prothrombin time (PT)/international normalized ratio (INR) < . x ULN and partial thromboplastin time (PTT) (activated [a]PTT) < . x ULN
Prothrombin time (PT)/international normalized ratio (INR) and partial thromboplastin time (PTT) =< . x institutional ULN
Prothrombin time (PT) < .  ULN or international normalized ratio (INR) < . and partial thromboplastin time (PTT) < .  ULN; unless the patient is on a therapeutic anticoagulant
Patients with abnormal prothrombin time (PT)/international normalized ratio (INR)/partial thromboplastin time (PTT) or bleeding diathesis
